

# Aris Persidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10684962/publications.pdf>

Version: 2024-02-01

36  
papers

1,145  
citations

643344

15  
h-index

425179

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1967  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 413-425.           | 1.3 | 23        |
| 2  | Literature analysis for systematic drug repurposing: a case study from Biovista. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2011, 8, 103-108.                          | 0.5 | 19        |
| 3  | Literature mining, ontologies and information visualization for drug repurposing. <i>Briefings in Bioinformatics</i> , 2011, 12, 357-368.   | 3.2 | 200       |
| 4  | Drug repurposing and adverse event prediction using high-throughput literature analysis. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2011, 3, 323-334. | 6.6 | 100       |
| 5  | Systems literature analysis. <i>Pharmacogenomics</i> , 2004, 5, 943-947.  | 0.6 | 15        |
| 6  | Strategies of biotechnology firms towards new, platform technologies. <i>International Journal of Biotechnology</i> , 2001, 3, 23.  | 1.2 | 5         |
| 7  | Data mining in biotechnology. <i>Nature Biotechnology</i> , 2000, 18, 237-238.  | 9.4 | 7         |
| 8  | Arthritis drug discovery. <i>Nature Biotechnology</i> , 1999, 17, 726-728.  | 9.4 | 4         |
| 9  | Bioinformatics. <i>Nature Biotechnology</i> , 1999, 17, 828-830.  | 9.4 | 17        |
| 10 | Cardiovascular disease drug discovery. <i>Nature Biotechnology</i> , 1999, 17, 930-931.   | 9.4 | 6         |
| 11 | Autoimmune disease drug discovery. <i>Nature Biotechnology</i> , 1999, 17, 1038-1038.   | 9.4 | 15        |
| 12 | Consolidations in biotechnology. <i>Nature Biotechnology</i> , 1999, 17, BE3-BE4.   | 9.4 | 1         |
| 13 | Cancer multidrug resistance. <i>Nature Biotechnology</i> , 1999, 17, 94-95.   | 9.4 | 284       |
| 14 | Mental disorder drug discovery. <i>Nature Biotechnology</i> , 1999, 17, 307-309.  | 9.4 | 4         |
| 15 | Biotechnology 2000. <i>Nature Biotechnology</i> , 1999, 17, 1239-1239.  | 9.4 | 1         |
| 16 | Biochips: An Evolving Clinical Technology. <i>Hospital Practice (1995)</i> , 1999, 34, 67-85.   | 0.5 | 14        |
| 17 | Signal transduction as a drug-discovery platform. <i>Nature Biotechnology</i> , 1998, 16, 1082-1083.  | 9.4 | 43        |
| 18 | Lead validation platforms. <i>Nature Biotechnology</i> , 1998, 16, 100-101.   | 9.4 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The business of pharmacogenomics. Nature Biotechnology, 1998, 16, 209-210.  | 9.4 | 36        |
| 20 | Functional antigenics. Nature Biotechnology, 1998, 16, 305-307.   | 9.4 | 2         |
| 21 | Proteomics. Nature Biotechnology, 1998, 16, 393-394.  | 9.4 | 72        |
| 22 | High-throughput screening. Nature Biotechnology, 1998, 16, 488-489.   | 9.4 | 66        |
| 23 | Combinatorial chemistry. Nature Biotechnology, 1998, 16, 691-693.   | 9.4 | 6         |
| 24 | Pharmacogenomics and diagnostics. Nature Biotechnology, 1998, 16, 791-792.  | 9.4 | 23        |
| 25 | Biochips. Nature Biotechnology, 1998, 16, 981-983.  | 9.4 | 24        |
| 26 | Biotechnology in 1998 and beyond. Nature Biotechnology, 1998, 16, 1378-1379.  | 9.4 | 5         |
| 27 | Pharmacogenomics and diagnostics. Nature Biotechnology, 1998, 16, 20-21.  | 9.4 | 4         |
| 28 | Bioentrepreneurship around the world. Nature Biotechnology, 1998, 16, 3-4.  | 9.4 | 43        |
| 29 | The carbohydrate-based drug industry. Nature Biotechnology, 1997, 15, 479-480.  | 9.4 | 17        |
| 30 | Critical issues in gene therapy commercialization. Nature Biotechnology, 1997, 15, 689-690.                             | 9.4 | 6         |
| 31 | Biotechnology valuation. Nature Biotechnology, 1997, 15, 813-814.   | 9.4 | 1         |
| 32 | Ribozyme therapeutics. Nature Biotechnology, 1997, 15, 921-922.   | 9.4 | 21        |
| 33 | Artificial intelligence for drug design. Nature Biotechnology, 1997, 15, 1035-1036.                                     | 9.4 | 6         |
| 34 | Catalytic antibodies. Nature Biotechnology, 1997, 15, 1313-1315.  | 9.4 | 5         |
| 35 | Biotechnologies to watch. Nature Biotechnology, 1997, 15, 1409-1411.  | 9.4 | 11        |
| 36 | Biotechnology consortia versus multifirm alliances: Paradigm shift at work?. Nature Biotechnology, 1996, 14, 1657-1660. | 9.4 | 9         |